Information needs and decision making preferences of older women offered a choice between surgery and primary endocrine therapy for early breast cancer

ConclusionsWomen strongly preferred face to face information. Written formats were also helpful, but not computer based resources. Information that was found helpful to women in the DM process was identified. The study demonstrates many women achieved their preferred DM style, with a preference for involvement, and expressed low levels of decision regret.
Source: Psycho-Oncology - Category: Cancer & Oncology Authors: Tags: PAPER Source Type: research

Related Links:

Dr Lowenfels challenges the findings of a recent study that suggests surgery as the better option in treating older women with early-stage breast cancer.Medscape General Surgery
Source: Medscape Today Headlines - Category: Consumer Health News Tags: General Surgery Viewpoint Source Type: news
Conclusion: ER+PR-HER2- breast cancer consists of clinically and genomically distinct groups that may require different treatment strategies. The non-luminal-like subgroup was associated with reduced benefit from endocrine therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
ConclusionThe determinants of non-adherence and non-persistence are multi-dimensional and influenced by several factors. The three categories of adherence barriers should be evaluated and considered when designing future interventions to enhance OET adherence for a tailored approach.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Condition:   Breast Neoplasm Intervention:   Sponsors:   St. Olavs Hospital;   Norwegian University of Science and Technology Not yet recruiting
Source: - Category: Research Source Type: clinical trials
In breast cancer, 17β-estradiol (E2) plays critical roles mainly by binding to its canonical receptor, estrogen receptor (ER) α66, and eliciting genomic effects. E2 also triggers rapid, nongenomic responses. E2 activates sphingosine kinase 1 (SphK1), increasing sphingosine-1-phosphate (S1P) that binds to its receptors, leading to important breast cancer signaling. However, the E2 receptor responsible for SphK1 activation has not yet been identified. Here, we demonstrate in triple-negative breast cancer cells, which lack the canonical ERα66 but express the novel splice variant ERα36, that ERα36 ...
Source: The Journal of Lipid Research - Category: Lipidology Authors: Tags: Research Articles Source Type: research
Purpose of review This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy in premenopausal women with estrogen receptor-positive early breast cancer. Recent findings Until recently, tamoxifen alone was the only recommended adjuvant treatment option for premenopausal women with estrogen receptor-positive disease. However, recent important evidence has contributed to significantly modify the endocrine treatment landscape in this setting. Summary With the only exception of patients with low-risk clinic...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BREAST CANCER: Edited by Giuseppe Curigliano Source Type: research
Conclusion: In endocrine therapy resistant breast cancer cells Fulvestrant is ineffective in decreasing ER α levels. Our data suggest that in the ETR cells,H19 expression acts as an ER modulator and that its levels and subsequently ER α levels can be substantially decreased by blocking Notch and c-MET receptor signaling. Consequently, treating ETR cells with these pharmacological inhibitors helps overcome resistance to Fulvestrant and Tamoxifen.Cell Physiol Biochem 2018;51:1518 –1532
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in theESR1 (estrogen receptor alpha (ER α)) gene ligand-binding domain (LBD) represent a recognized mechanism of acquired resistance. Antiestrogens with improved efficacy versus tamoxifen might overcome the resistant phenotype in ER+ breast cancers. Bazedoxifene (BZA) is a potent antiestrogen that is clinically approved for use in hormon e replacement therapies. We found that BZA possesses improved inhibitory potency against the Y537S and D538G ERα mutants compared to tamoxifen and has ad...
Source: eLife - Category: Biomedical Science Tags: Cancer Biology Source Type: research
In conclusion, DCIS patients with positive hormone receptors should be recommended to receive endocrine therapy. Selection of TAM or ANA is based on clinical characteristics and underlying disease of patients, as well as the side-effects of drugs. PMID: 30499075 [PubMed - as supplied by publisher]
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.Endocrine therapy has become an essential part of treatment for the many women diagnosed with hormone-receptor positive breast cancer, in which hormones, such as estrogen, promote cancer growth. The endocrine treatment helps lower the recurrence and reduce the risk of death from breast cancer by interfering with how a woman ’s own hormones can continue to support the growth of dormant cancer cells. Yet, there has been limited evidence ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Computers | Endocrine Therapy | Nurses | Nursing | Study | Women